Research & Development at Medochemie
At Medochemie, Research & Development is a strategic driver of innovation, scientific rigor, and global competitiveness in the field of generic pharmaceuticals. Our mission is to develop high-quality, affordable medicines that meet international standards and improve healthcare access worldwide.
Our R&D framework integrates advanced technology platforms, regulatory excellence, and highly specialized teams, positioning us at the forefront of generic drug development across multiple dosage forms and therapeutic categories.
Scientific Excellence and Integrated Capabilities
Medochemie’s R&D centres are equipped with state-of-the-art infrastructure that supports end-to-end pharmaceutical development, from reformulation to technology transfer. Our multidisciplinary teams comprise experienced formulation scientists, analytical chemists, clinical experts, and intellectual property professionals, many of whom hold postgraduate and doctoral degrees in pharmaceutical sciences.
Each product is developed through a structured, science-based approach guided by international regulatory frameworks, including ICH Q8–Q10, WHO-GMP, and EU directives. Robust project governance, coupled with a deep understanding of industrial pharmacy, underpins our ability to meet evolving global regulatory expectations.
Core Pillars of Our R&D Platform
Our scientists develop robust, bioequivalent generic formulations, ranging from conventional dosage forms to technologically complex and modified-release systems. The team applies quality-by-design (QbD) principles, ensuring each formulation meets target product profiles and regulatory standards.
Our analytical laboratories support method development, validation, and transfer using advanced technologies such as HPLC, GC-MS, FTIR, UV-Vis, ion chromatography, and rheological analysis. Capabilities include stability studies, in vitro release testing, impurity profiling, and nitrosamine risk assessment.
With deep expertise in bioequivalence study design and regulatory compliance, our clinical development team ensures that dossier submissions are supported by high- quality data, aligned with EMA, FDA, and other international standards.
Our dedicated tech transfer team oversees the seamless scale-up and transfer of products from development to commercial manufacturing. Transfers are managed in accordance with WHO and ISPE guidelines, ensuring reproducibility and process integrity.
IP specialists are engaged early in the development process to ensure full freedom-to- operate and protection of know-how. They provide strategic oversight to avoid infringement risks and support timely, compliant product launches.
Each development program is managed by qualified scientists trained in project management methodologies. Using advanced software tools, they ensure efficient cross- functional coordination, timeline adherence, and regulatory readiness.
Our analytical laboratories support method development, validation, and transfer using advanced technologies such as HPLC, GC-MS, FTIR, UV-Vis, ion chromatography, and rheological analysis. Capabilities include stability studies, in vitro release testing, impurity profiling, and nitrosamine risk assessment.
With deep expertise in bioequivalence study design and regulatory compliance, our clinical development team ensures that dossier submissions are supported by high- quality data, aligned with EMA, FDA, and other international standards.
Our scientists develop robust, bioequivalent generic formulations, ranging from conventional dosage forms to technologically complex and modified-release systems. The team applies quality-by-design (QbD) principles, ensuring each formulation meets target product profiles and regulatory standards.
IP specialists are engaged early in the development process to ensure full freedom-to- operate and protection of know-how. They provide strategic oversight to avoid infringement risks and support timely, compliant product launches.
Each development program is managed by qualified scientists trained in project management methodologies. Using advanced software tools, they ensure efficient cross- functional coordination, timeline adherence, and regulatory readiness.
Our dedicated tech transfer team oversees the seamless scale-up and transfer of products from development to commercial manufacturing. Transfers are managed in accordance with WHO and ISPE guidelines, ensuring reproducibility and process integrity.
Broad Technological Reach
Our R&D capabilities cover a wide range of dosage forms, including:
- Oral solids (immediate and modified release tablets, capsules, powders, pellets)
- Parenterals (injectable solutions)
- Topical formulations (gels, creams, suppositories)
- Oral liquids (solutions, suspensions)
- Dietary supplements
Development processes are supported by equipment that simulates full-scale manufacturing, including roller compaction, fluid bed granulation, and automated film coating systems. In- process control and PAT tools ensure quality consistency throughout scale-up.
With a foundation of scientific depth, regulatory expertise, and continuous innovation, Medochemie’s R&D remains central to our mission to deliver trusted medicines that meet real-world healthcare needs.
